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Abstract  
We described bacterial killing and resistance emergence at various fixed concentrations of 
meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia 
coli. Time-kill studies were conducted utilizing nine isolates and a large range of 
concentrations. Within each strain and antibiotic, initial killing was similar, with 
concentrations ≥2×MIC. At many (strain-specific) concentrations causing substantial initial 
killing, regrowth occurred at 24-48h. For remaining concentrations, growth typically remained 
suppressed (<5-log10 cfu/mL). The concentrations of meropenem required to suppress 
regrowth ranged from 2–8×MIC for P. aeruginosa and 2–64×MIC for E. coli. For 
piperacillin/tazobactam, the equivalent concentrations ranged from 8–16×MIC for P. 
aeruginosa and 4–16×MIC for E. coli. The number of less-susceptible bacteria increased 
with rising concentrations before decreasing at even higher concentrations. Suppression of 
regrowth and resistance was substantially improved with higher concentrations (typically 
≥8×MIC), suggesting a benefit of higher β-lactam concentrations beyond those required for 
maximum initial killing. 
 
Key words: bacterial killing; resistance; beta-lactam antibiotics; in vitro studies 
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1. Introduction 
  Infections in critically ill patients are common and cause significant morbidity and 
mortality [1-3]. While early administration of effective antibiotic therapy improves survival 
substantially [4, 5], resistance to antibiotic therapy nevertheless develops in many of these 
patients often leading to therapeutic failure and death [3]. Indeed, while the incidence of 
multidrug-resistant (MDR) pathogens is increasing generally, it is especially the case in 
critically ill patients [3]. Worryingly, as many previously simple infections become 
increasingly difficult to treat with existing therapeutic options [6], the development of new 
antibiotics has stagnated. A potential contributing factor to the emergence of resistance is 
sub-optimal dosing of antibiotics, especially in critically ill patients where severely altered 
and variable antibiotic pharmacokinetics are often observed [7, 8]. While traditional 
approaches for antibiotic administration have been developed in accordance with 
pharmacokinetic/pharmacodynamic (PK/PD) principles that sought to maximise bacterial 
killing, emerging data suggests dosing approaches should also aim to minimise the 
emergence of resistance [9]. Thus, there is an urgent need to optimise the use of currently 
available treatments both in terms of bacterial killing and resistance emergence. 
Unfortunately, exposure-effect relationships for suppression of the emergence of resistance 
have not been well characterised [7, 9]. 
  The Gram-negative pathogens Pseudomonas aeruginosa and Escherichia coli are 
among the most critical ‘superbugs’ identified by the Infectious Diseases Society of America 
(IDSA) [10]. They are frequent causes of serious infection in critically ill patients and are 
commonly treated with the β-lactam antibiotics meropenem and piperacillin/tazobactam [11]. 
However, P. aeruginosa and E. coli can rapidly develop resistance to meropenem and 
piperacillin/tazobactam following sub-optimal exposure [12-14]. Data on exposures to these 
antibiotics that both maximise bacterial killing and suppress the emergence of resistance is 
required to optimise treatment outcomes for infected critically ill patients. The aim of this 
study was to examine the relationship between increasing concentrations of meropenem and 
piperacillin/tazobactam and the extent of bacterial killing and suppression of regrowth and 
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emergence of resistance for clinical isolates of P. aeruginosa and E. coli. 
2. Materials and Methods: 
2.1. Bacterial strains and susceptibility testing 
Three clinical isolates of P. aeruginosa (1280, 1281 and 1283), four clinical isolates 
of E. coli (JB IMP, CMY, St131 and 713), plus a reference strain of each species (ATCC 
27853 for P. aeruginosa and ATCC 25922 for E. coli) were employed. The clinical isolates 
were obtained from critically ill patients at the Royal Brisbane and Women’s Hospital 
(Brisbane, Australia). Minimum inhibitory concentrations (MICs) of meropenem (Hospira, 
Melbourne, Australia) and piperacillin/tazobactam (Aspen, New South Wales, Australia) 
were determined by agar dilution on cation-adjusted Mueller-Hinton agar (CAMHA, 
containing 25 mg/L Ca2+ and 12.5 mg/L Mg2+; BD, Sparks, MD, USA) in duplicate on 
separate days in accordance with CLSI guidelines [15]. As per the EUCAST guidelines, 
susceptibility and resistance was defined as an MIC of ≤2 mg/L and >8 mg/L for meropenem 
against both P. aeruginosa and E. coli, and for piperacillin/tazobactam an MIC of ≤16 mg/L 
and >16 mg/L for P. aeruginosa and ≤8 mg/L and >16 mg/L for E. coli [16]. Isolates were 
stored in cation-adjusted Mueller-Hinton II broth (CAMHB, containing 25 mg/L Ca2+ and 12.5 
mg/L Mg2+; BD, Sparks, MD, USA,) with 20% glycerol at -80°C and subcultured onto MHA 
prior to use. For all experiments stock solutions of antibiotic were prepared in Milli-Q water, 
sterilized by passage through a 0.22 µm polyvinylidene fluoride (PVDF) filter, and stored at -
80°C.  
2.2. Time kill studies and emergence of resistance 
Bacterial killing and emergence of resistance was examined using time-kill studies at 
an initial inoculum of ~105.5 cfu/mL over 48 h. Briefly, one colony was grown overnight in 
CAMHB at 37°C, and the optical density determined spectrophotometrically at 620 nm 
(Genesys 20, Thermo Scientific). A previously established equation between the optical 
density and the bacterial concentration in cfu/mL was used to attain the desired inoculum, 
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with an appropriate volume of the bacterial suspension added to sterile 50 mL polypropylene 
tubes (Thermofisher, Melbourne, Australia) containing 20 mL of sterile, pre-warmed CAMHB. 
Following inoculation meropenem (range, 0.016 - 128 mg/L) or piperacillin (range, 0.125 - 
256 mg/L) was added (t = 0 h) to achieve the desired (fixed) concentration, and tubes 
incubated in a shaking water bath at 36°C. Concentrations were adjusted based on the MIC 
of the organism. To compensate for the known thermal degradation of β-lactam antibiotics 
[17], at 24 h bacterial suspensions were centrifuged for 10 min at 3220 g and 36°C, and the 
supernatant removed and replaced with pre-warmed, antibiotic-containing sterile CAMHB 
(100% of the initial antibiotic concentration corresponding to the volume of CAMHB). 
Controls were similarly treated but replaced with sterile antibiotic-free CAMHB. Because of 
the greater thermal degradation of meropenem, this antibiotic was additionally supplemented 
at 30% of the initial concentration at 6 and 30 h [17]. 
Serial samples were collected aseptically for total viable counting at 0, 1.5, 3, 5, 24, 
25, 29 and 48 h, and for quantification of resistant bacteria at 0, 24, and 48 h. To minimize 
antibiotic carryover, samples were twice centrifuged at 4,000 g for 5 min and re-suspended 
in saline. For total viable counting, 100 µL of appropriately diluted sample was then manually 
plated onto CAMHA plates (containing 25 mg/L Ca2+ and 12.5 mg/L Mg2+; Media Preparation 
Unit, University of Melbourne, Australia). Given the potential for a low number of resistant 
bacteria in samples from untreated controls and some treatment regimens, 200 µL of 
appropriately diluted sample was plated onto CAMHA containing meropenem or 
piperacillin/tazobactam at 3× and 5× MIC in order to increase sensitivity. For determination 
of total and resistant counts at baseline (0 h), log-phase growth suspension was used. 
Enumeration for both total viable counts and resistant counts was performed manually after 
24 h of incubation (48 h for plates with small colonies) at 36°C. Based on the total viable and 
resistant counts, the log10 mutation frequency (log10 MF) was determined as follows: 
log10MF = log10(cfu/mL on antibiotic-containing agar) - log10(cfu/mL on antibiotic-free agar) 
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Although some viable counts at 24 and 48 h were too low to enable quantification of colonies 
on antibiotic-containing agar, these arms nevertheless provided information on the upper 
limit of the log10MF. To confirm changes in MIC from baseline, in a subset of experiments 
MICs were determined at 24 and 48 h as described above using at least three colonies from 
each antibiotic-containing plate. 
3. Results 
3.1. Bacterial susceptibilities and time-kill kinetics  
The MICs to each antibiotic for all strains are shown in Table 1. For each antibiotic, 
time course profiles of bacterial numbers achieved with selected isolates are presented in 
igure 1 (meropenem) and Figure 2 (piperacillin/tazobactam). The complete time-kill data for 
all isolates are presented in colour in the Supplementary data (available online). For each 
strain and with each antibiotic, the rate and extent of bacterial killing across the first 5 h was 
generally similar (within ~1 – 2 log10 cfu/mL) once concentrations reached 2× MIC. At this 
time, maximum killing against P. aeruginosa was ~3.0 log10 cfu/mL with meropenem and 
ranged from ~3.0 – 4.5 log10 cfu/mL with piperacillin/tazobactam. The equivalent values for 
E. coli were ~5.5 log10 with meropenem and from ~3.5 – 5.0 log10 with 
piperacillin/tazobactam.  
For both antibiotics and pathogens, regrowth above the initial inoculum and, on many 
occasions, to within ~1 – 2 log10 cfu/mL of growth controls had occurred by 24 h (Figures 1 
and 2) with many concentrations which caused substantial initial killing. The concentrations 
at which this occurred were strain-specific. In five cases, substantial regrowth occurred at 
48 h with one or more concentrations that had suppressed regrowth at 24 h. For the 
remaining concentrations, growth typically remained suppressed (below 5 log10 cfu/mL) 
across 48 h without bacterial eradication. The lowest meropenem concentrations that 
suppressed regrowth to <5 log10 cfu/mL at both 24 and 48 h ranged from 2× to 8× MIC for P. 
aeruginosa and 2× to 64× MIC for E. coli, with most isolates requiring ≥8× MIC (Table 2). 
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The concentrations required to suppress regrowth at 48 h were in most cases the same as 
those at 24 h; a significant increase (from 2× to 64× MIC) occurred only in the E. coli 
reference strain.  
For piperacillin/tazobactam across all isolates, the lowest concentrations suppressing 
regrowth ranged from 4× – 16× MIC at 24 h for both pathogens. In 3 of the 7 isolates double 
that concentration was required to suppress regrowth at 48 h (Table 2). Log10 differences in 
bacterial killing at 24 and 48 h between the lowest growth-suppressing meropenem 
concentration and half this concentration ranged from ~2.5 to 5 log10 cfu/mL against 
P. aeruginosa and ~3.5 to 7.5 log10 cfu/mL against E. coli. For piperacillin/tazobactam, these 
log10 differences were ~2 – 4 log10 cfu/mL against P. aeruginosa and ~2.5 – 5.5 log10 cfu/mL 
against E. coli. 
 
Table 1. Baseline (0 h) MICs and mutation frequencies (log10MF)
a of meropenem and 
piperacillin/tazobactam for isolates used in this studyb 
   
 
Isolate 
Mero Pip/Taz 
  
      
MIC
c
 
(mg/L) 
log10MF 
(3× MIC) 
log10MF 
(5× MIC) 
MIC
d
 
(mg/L) 
log10MF 
(3× MIC) 
log10MF 
(5× MIC) 
       
       
P. aeruginosa       
ATCC 27853 0.25 -6.16 <-7.54 2 -6.12 -6.38 
1280 0.25 -5.24 -6.49 4 <-7.38 <-7.38 
1281 1 <-7.30 <-7.30 4 -5.67 -6.07 
1283 1 -6.82 <-7.20 4 -5.28 -5.65 
       
E. coli       
ATCC 25922 0.016 <-7.54 <-7.54 2 <-7.74 <-7.74 
JB IMP 0.25 -3.74 -3.69 - - - 
CMY 0.031 -5.78 -6.75 - - - 
St131 - - - 2 -6.70 <-7.60 
713 - - - 8 -7.13 <-7.30 
       
a
 Mutation frequencies were determined at 3× MIC and 5× MIC for each antibiotic. <, no colonies 
observed on drug-containing agar plates, thus the upper limit is reported. 
b
 Mero, meropenem; Pip/Taz, piperacillin/tazobactam. 
c
 EUCAST breakpoints for meropenem were ≤2 mg/L for susceptibility and >8 mg/L for resistance for 
both P. aeruginosa and E. coli. 
d
 EUCAST breakpoints for piperacillin/tazobactam were ≤16 mg/L for susceptibility and >16 mg/L for 
resistance for P. aeruginosa. For E. coli, the breakpoints were ≤8 mg/L for susceptibility and >16 mg/L 
for resistance. 
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Figure 1. Representative time-kill curves for meropenem against clinical isolates of P. aeruginosa (A) 1280 and (B) 1283, and E. coli (C) JB 
IMP and (D) CMY. The y-axis starts from the limit of detection. All isolates are presented in colour in the Supplementary data. Mero, 
meropenem.  
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Figure 2. Representative time-kill curves for piperacillin/tazobactam against clinical isolates of P. aeruginosa (A) 1280 and (B) 1283, and E. coli 
(C) 713 and (D) St 131. The y-axis starts from the limit of detection. All isolates are presented in colour in the Supplementary data. Pip/Taz, 
piperacillin/tazobactam. 
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Table 2.  Lowest fixed concentration (LCC; in multiples of MIC) that suppressed regrowth* of the total population and log10 cfu/mL differences 
(∆log10 cfu/mL) in bacterial killing between this concentration and half this concentration (i.e. one dilution below) at 24 and 48 h. 
   
 
 
Isolate 
 
Mero Pip/Taz 
  
    
LCC ∆log10 cfu/mL LCC ∆log10 cfu/mL 
    
        
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 
         
         
P. aeruginosa         
ATCC 27853 8× MIC 8× MIC 2.48 5.14 16× MIC 16× MIC 1.85 3.74 
1280 8× MIC 8× MIC 3.12 5.15 8× MIC   8× MIC 1.80 3.71 
1281 2× MIC 2× MIC 4.26 3.46 8× MIC 16× MIC 1.69 4.67 
1283 2× MIC 2× MIC 4.27 4.05 16× MIC 16× MIC 2.96 4.02 
             
E. coli             
ATCC 25922 2× MIC 64× MIC 7.04 6.08 4× MIC 4× MIC 3.97 3.56 
JB IMP 32× MIC 32× MIC 4.78 6.90 - - - - 
CMY 8× MIC 16× MIC 3.67 7.64 - - - - 
St131 - - - - 8× MIC 16× MIC 2.32 4.90 
713 - - - - 8× MIC 16× MIC 5.66 5.76 
         
* Defined as growth remaining below 5 log10 cfu/mL. 
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3.2. Emergence of bacterial resistance 
The log10MF of each isolate against meropenem and piperacillin/tazobactam prior to 
antibiotic treatment (i.e. at baseline) are presented in Table 1. Bacterial counts on 3× and 5× 
MIC antibiotic-containing agar plates at 24 and 48 h are reported in Table 3; MICs of 
colonies from these agar plates confirmed resistance/decreased susceptibility (Table 4). The 
log10MF at 24 and 48 h are located in the supplemental material (Tables S1 and S2). Very 
low fixed concentrations of either drug against either organism generally had little or no 
impact on the number of less-susceptible bacteria growing on 3× and 5× MIC plates at 24 
and 48 h compared to growth controls. With increasing concentrations, the number of less-
susceptible bacteria tended to increase (up to a maximum of ~5 log10 cfu/mL) over a range 
of concentrations (strain dependent) and then decrease again as concentrations increased 
further. Generally, at 1× or ½× the multiple of the MIC that suppressed regrowth, the 
absolute number of resistant bacteria fell to below the number observed in the growth control 
at the same time point (24 or 48 h). On many occasions, there were no less-susceptible 
bacteria detected with these, or greater, fixed concentrations. The log10MF most often 
remained similar to that of the growth control at very low concentrations of either drug, but 
generally increased several orders of magnitude as concentrations increased towards that 
required to suppress regrowth. Once regrowth was suppressed, further increases in 
concentration resulted in either no less-susceptible colonies being detected or the log10MFs 
remaining very high. The latter situation indicates an overall high percentage of resistant 
bacteria even though total regrowth was minimal and the absolute numbers of resistant 
bacteria were very low. 
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Table 3. Log10 bacterial counts on agar containing meropenem (Mero) and piperacillin/tazobactam (Pip/Taz) at 3× and 5× MIC for each strain. 
The fixed concentrations (in multiples of the MIC) that suppressed regrowth of the total population are bolded. 
Multiple of MIC 
Log10 cfu/mL 
Pa 27853 Pa 1280 Pa 1281 Pa 1283 EC 25922 Ec JB IMP Ec CMY Ec ST131 Ec 713 
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 
M
e
ro
 3
× 
M
IC
 
0 2.40 2.90 4.28 4.48 2.19 2.78 2.65 3.58 3.06 5.90 5.68 5.30 4.27 8.48     
0.063 - - - - - - - - - - 8.58 8.38 - -     
0.125 - - - - - - - - - - 8.70 7.79 - -     
0.25 4.23 5.76 - - - - - - - - 8.72 8.05 - -     
0.5 5.64 6.59 - - 8.73 8.85 - - - - 8.75 8.49 5.67 5.70     
1 7.39 7.54 7.40 8.32 4.72 5.52 5.15 3.24 2.62 7.58 8.70 7.75 8.16 8.74     
2 8.62 7.89 7.13 9.20 <0.70 1.48 <0.70 0.70 1.18 7.58 8.62 7.89 - -     
4 1.11 1.70 3.70 5.11 <0.70 <0.70 <0.70 1.30 1.95 6.56 5.70 6.43 6.95 7.22     
8 <0.70 1.54 <0.70 1.90 <0.70 0.70 <0.70 1.00 2.02 5.90 8.61 8.78 1.60 6.60     
16 <0.70 <0.70 <0.70 2.18 - - <0.70 0.70 1.00 5.28 2.18 5.78 2.00 1.54     
32 2.22 4.63 <0.70 1.00 <0.70 <0.70 <0.70 1.00 1.74 1.54 2.04 2.10 <0.70 1.54     
64 1.98 2.31 - - <0.70 0.70 <0.70 1.18 2.43 2.64 1.30 2.48 <0.70 2.02     
128 1.18 2.44 <0.70 0.70 <0.70 0.70 <0.70 0.70 1.18 1.95 1.54 3.22 - -     
256 <0.70 1.00 <0.70 1.18 - - - - - - - - 1.18 <0.70     
512 <0.70 <0.70 <0.70 <0.70 - - - - - - 1.30 2.62 - -     
1024 - - - - - - - - <0.70 1.70 - - - -     
2048 - - - - - - - - <0.70 0.70 - - <0.70 <0.70     
4096 - - - - - - - - - - - - - -     
8192 - - - - - - - - <0.70 1.00 - - - -     
P
ip
/T
az
 3
× 
M
IC
 
0 3.21 3.65 1.70 3.70 3.06 3.60 3.56 3.98 <0.70 1.65         1.18 5.95 4.03 3.38 
0.063 3.24 3.74 - - - - - - <0.70 1.95     2.08 7.15 - - 
0.125 - - - - - - - - - -     - - - - 
0.25 3.05 3.42 0.70 2.30 3.11 3.64 3.40 4.19 <0.70 1.30     1.65 5.85 - - 
0.5 - - 2.16 3.35 5.06 5.75 6.00 6.96 - -     - - 3.80 3.45 
1 6.64 7.54 3.70 3.93 6.90 8.38 4.70 9.01 0.70 3.27     5.27 8.15 4.65 4.06 
2 8.04 9.07 3.48 3.60 8.41 8.76 8.52 8.98 <0.70 4.19     8.03 8.71 8.78 8.95 
4 7.95 8.70 2.04 3.06 6.00 7.63 - - <0.70 1.30     7.16 9.53 5.08 5.48 
8 7.09 7.95 <0.70 <0.70 2.90 5.43 7.52 7.92 <0.70 4.92     1.85 2.79 <0.70 5.57 
16 1.00 2.68 <0.70 <0.70 <0.70 2.80 3.26 2.48 <0.70 <0.70     2.20 2.73 <0.70 <0.70 
32 1.54 3.72 <0.70 <0.70 <0.70 2.78 1.85 3.34 - -     1.85 2.04 <0.70 <0.70 
64 - - <0.70 <0.70 <0.70 0.70 2.18 2.60 - -     3.03 4.11 - - 
128 3.26 2.91 - - - - - - <0.70 <0.70     1.65 3.00 - - 
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Table 3 (Cont.). 
Multiple of MIC 
Log10 cfu/mL 
Pa 27853 Pa 1280 Pa 1281 Pa 1283 EC 25922 Ec JB IMP Ec CMY Ec ST131 Ec 713 
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h 
M
e
ro
 5
× 
M
IC
 
0 1.48 2.96 2.55 2.81 <0.70 2.75 1.00 2.59 3.08 5.76 5.52 4.70 2.48 6.64     
0.063 - - - - - - - - - - 3.70 5.64 - -     
0.125 - - - - - - - - - - 3.70 5.04 - -     
0.25 2.10 3.39 - - - - - - - - 3.70 5.45 - -     
0.5 3.51 4.62 - - 6.54 8.26 - - - - 4.51 6.08 3.94 7.22     
1 4.48 4.20 6.58 7.64 2.06 4.45 3.76 3.27 <0.70 3.82 5.16 5.65 7.16 7.34     
2 5.27 5.95 5.37 6.20 <0.70 <0.70 <0.70 <0.70 1.40 5.54 5.27 5.95 1.00 1.48     
4 1.30 2.70 4.70 6.13 <0.70 <0.70 <0.70 <0.70 2.06 4.70 3.70 5.60 5.90 6.82     
8 <0.70 1.18 <0.70 1.00 <0.70 <0.70 <0.70 <0.70 2.15 4.70 7.15 7.50 1.60 1.30     
16 <0.70 <0.70 <0.70 2.26 - - <0.70 <0.70 0.70 4.78 1.70 4.88 <0.70 1.78     
32 2.28 5.02 <0.70 1.30 <0.70 <0.70 <0.70 <0.70 1.65 1.85 1.18 0.70 <0.70 1.93     
64 1.93 2.22 - - <0.70 <0.70 <0.70 <0.70 2.53 2.26 <0.70 1.54 0.70 <0.70     
128 <0.70 0.70 <0.70 <0.70 <0.70 <0.70 <0.70 <0.70 1.40 2.02 0.70 2.51 - -     
256 <0.70 <0.70 <0.70 <0.70 - - - - - - - - <0.70 0.70     
512 0.70 <0.70 <0.70 <0.70 - - - - - - <0.70 2.15 - -     
1024 - - - - - - - - <0.70 1.81 - - - -     
2048 - - - - - - - - <0.70 <0.70 - - <0.70 <0.70     
4096 - - - - - - - - - - - - - -     
8192 - - - - - - - - <0.70 <0.70 - - - -     
P
ip
/T
az
 5
× 
M
IC
 
0 2.76 3.24 0.70 1.70 2.65 3.04 4.40 3.78 <0.70 2.38     <0.70 5.48 2.18 1.70 
0.063 2.82 3.31 - - - - - - <0.70 2.42     1.54 7.04 - - 
0.125 - - - - - - - - - -     - - - - 
0.25 2.81 3.08 <0.70 1.70 2.69 3.57 3.26 3.86 <0.70 1.48     <0.70 5.72 - - 
0.5 - - 1.88 2.30 4.65 5.69 5.90 6.88 - -     - - 1.70 1.70 
1 6.35 7.29 3.15 4.11 7.54 8.19 4.70 9.00 <0.70 3.30     5.60 8.10 1.70 1.70 
2 7.98 8.77 2.95 3.64 8.13 8.60 7.96 6.70 <0.70 3.82     7.44 7.60 8.70 5.70 
4 7.87 8.44 1.18 4.16 5.79 6.78 - - <0.70 <0.70     3.15 7.60 4.08 4.10 
8 6.72 8.00 <0.70 0.70 1.95 4.87 7.10 8.05 <0.70 2.76     5.23 8.04 <0.70 2.40 
16 0.70 2.51 <0.70 <0.70 1.00 2.39 3.26 1.54 <0.70 <0.70     0.70 8.01 <0.70 <0.70 
32 1.30 3.97 <0.70 <0.70 0.70 2.42 1.88 2.83 - -     1.45 2.72 <0.70 <0.70 
64 - - <0.70 <0.70 <0.70 1.00 1.93 2.40 - -     2.81 4.02 - - 
128 3.10 3.16 - - - - - - <0.70 <0.70     1.00 2.81 - - 
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<0.70, no colonies observed on drug-containing agar plates, thus the quantification limit is reported. Green: ≤ growth control, white: up to 0.5 
log10 higher than growth control, orange: > 0.5 log10 higher than growth control. Where breakthrough growth occurred, i.e. a lawn on the lower 
dilution plates and no colony on the next dilution, a value of 1 on the lowest dilution with 0 colonies was assumed as the upper limit. This table 
appears in colour in the online version of DMID and in grey scale in the print version of DMID. 
 
 
Table 4. MIC values from colonies obtained from drug-containing (3× and 5× the baseline MIC) agar plates at 24 and 48 h from a subset of 
experiments in the time kill studiesa  
                    
  MIC
b,c
 
                    
                    
Antibiotic  Time 
(h) 
Pa 27853 Pa 1280 Pa 1281 Pa 1283 Ec 25922 Ec JB IMP Ec CMY Ec ST131 Ec 713 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
3× 
MIC 
5× 
MIC 
                    
                    
Mero 24 4 4 2 4 4 16 16 16 8 8 1 1 0.125 0.5 - - - - 
 48 4 4 4 4 4 16 16 16 0.5 0.5 1 1 - 0.5 - - - - 
                    
Pip/Taz 24 32 64 32 32 64 64 64 >64 16 - - - - - 16 32 64 64 
 48 64 64 32 64 64 64 64 64 64 64 - - - - 16 64 64 64 
                    
 
a
The experimental arms chosen contained the following concentrations of meropenem (Mero): 0.5 mg/L for P. aeruginosa 27853, 1280, and 1281; 1 mg/L for 
P. aeruginosa 1283; 0.031 mg/L for E. coli 25922 and CMY; 2 mg/L for E. coli JB IMP. The experimental arms containing piperacillin/tazobactam (Pip/Taz) 
used concentrations of: 4 mg/L for P. aeruginosa 27853 and 1280 and E. coli ST131; 8 mg/L for P. aeruginosa 1281 and 1283; 2 mg/L for E. coli 25922 and 
16 mg/L for E. coli 713. 
b
Susceptibility and resistance was defined as an MIC of ≤2 mg/L and >8 mg/L for meropenem against both P. aeruginosa and E. coli, and for 
piperacillin/tazobactam an MIC of ≤16 mg/L and >16 mg/L for P. aeruginosa and ≤8 mg/L and >16 mg/L for E. coli, as per EUCAST guidelines. 
c
MICs at baseline (0 h; determined from the total bacterial population) were as follows: For Mero, 0.013 mg/L for Ec CMY; 0.016 mg/L for Ec 25922; 0.25 
mg/L for Pa 27853, Pa 1280, and Ec JB IMP; 1 mg/L for Pa 1281 and Pa 1283. For Pip/Taz, 2 mg/L for Pa 27853, Ec 25922, and Ec ST131; 4 mg/L for Pa 
1280, Pa 1281, and Pa 1283; 8 mg/L for Ec 713. 
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4. Discussion 
Beta-lactam antibiotics such as meropenem and piperacillin are very commonly used 
[11]. PK/PD approaches for dose optimization of β-lactam antibiotics have traditionally 
sought to maximize the fT>MIC, i.e. the fraction of the dosing interval for which the unbound 
concentration remains above 1× MIC of the infecting pathogen, to improve patient outcomes 
[18, 19]. For example for cephalosporins, penicillins, and carbapenems, bacteriostasis 
requires an fT>MIC of 35 – 40%, 30%, and 20% respectively [18, 20, 21]. To achieve near 
maximal bacterial killing higher values of 60 – 70%, 50% and 40%, respectively, have been 
reported. This approach, which aims to optimise drug exposures for bacterial killing, is based 
on the monotonic relationship between drug exposure (e.g. fT>MIC) and bacterial killing 
whereby there is no measurable killing at very low exposures with increasing killing as 
exposure increases up to a maximal value. Most studies examining such exposures are 
conducted over short periods of time (≤24 h) using a limited number of isolates. Additionally, 
the relationship between exposure and the emergence of resistance is distinctly non-
monotonic (with a shape similar to an inverted “U”); [12, 22]  very few studies examine this 
relationship. Thus, markedly increased antibiotic exposures may be required to suppress the 
emergence of resistance; such has been shown for the fluoroquinolones [23-25], 
aminoglycosides [25], and β-lactams [26]. We therefore sought to examine the relationship 
between increasing fixed concentrations of meropenem and piperacillin/tazobactam on 
bacterial killing and emergence of resistance over 48 h using a larger number of isolates and 
a wide range of β-lactam concentrations. 
In this study we identified a strain-dependent concentration (in multiples of the MIC) 
that was required to suppress regrowth. Unlike the traditional fT>MIC target which is based on 
concentrations exceeding 1× MIC, the concentration suppressing regrowth was as least 2× 
MIC for meropenem but more often 8× to 16× MIC for both antibiotics against both species. 
The absolute number of less-susceptible bacteria tended to increase over a range of lower 
fixed concentrations and then decrease again as concentrations approached that which 
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suppressed regrowth, akin to the inverted “U” shape linking drug exposure to suppression of 
a resistant subpopulation described previously [12, 22]. However, on many occasions the 
log10MFs remained very high even after growth was suppressed. This indicates that in these 
instances the proportion of less-susceptible bacteria in the total populations that regrew was 
very high. Nevertheless, at fixed concentrations at or exceeding those required for regrowth 
suppression, the overall bacterial burden for both the susceptible and less-susceptible 
populations was low. 
Our results indicated that fixed concentrations of each antibiotic greatly exceeding 
the MIC of the organism have minimal advantages in terms of initial bacterial killing, e.g. 
over the first 5 h. This is in agreement with the well-accepted PK/PD targets for β-lactams 
(fT>MIC 40% to 100%). Importantly however, there may be potentially significant benefits of 
increased drug exposures for both bacterial killing and suppression of the emergence of 
resistant organisms at later times (e.g. 24 and 48 h). Our data is in accordance with previous 
data generated primarily using P. aeruginosa which indicates β-lactam exposures close to 
the MIC do not provide persistent bactericidal activity and that higher concentrations may be 
required to prolong bacterial killing. To the best of our knowledge, this is the first time this 
has been demonstrated for E. coli; we assess this question in a large number of isolates and 
over a wide range of β-lactam concentrations. Moreover, very few studies examining the 
benefits of increased drug exposures for bacterial killing against any organism have 
additionally investigated the emergence of resistance.  
In an early study, Mouton et al. [27] showed bacterial killing of three strains of 
P. aeruginosa by ceftazidime persisted for only a short time (~8 h) when a sustained 
concentration (delivered as a continuous infusion) was maintained at or slightly above the 
MIC. However, sustained concentrations higher than 4× MIC were required to suppress 
regrowth over 36 h. These observations suggest higher exposures may be required to 
prevent regrowth of resistant organisms. Feng et al. [28] showed that regrowth is very likely 
to occur within days of commencement of therapy after exposure of wild type P. aeruginosa 
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to the highest concentrations of meropenem and ceftazidime expected in patients receiving 
clinically used doses (1 g iv bolus infusion administered over 30 min 8-hourly and 1 g iv 
loading dose followed by a continuous infusion of 3000 mg over 24 h, respectively). Stearne 
et al. [26] found an fAUC/MIC of ~1,000 would be required to suppress the selection of 
ceftriaxone-resistant Enterobacter cloacae mutants. This value is much higher than the value 
needed for maximal bacterial killing based on fT>MIC. Using a hollow-fiber infection model 
(HFIM) with a fixed Cmax of 57.2 mg/L (considerably lower than the highest concentration 
used in the present study) and varying half-lives, Tam et al. [12] demonstrated that regrowth 
of a single wild-type strain of P. aeruginosa and its isogenic mutant exposed to meropenem 
occurred within days when the Cmin/MIC was ≤1.7× MIC. They also found that a Cmin/MIC 
>6× MIC was required to suppress regrowth of a resistant sub-population.  
Recently, we investigated both meropenem [14] and piperacillin/tazobactam [13] in a 
HFIM against P. aeruginosa 1280 across 7 – 10 days.  Although the primary purpose of 
those studies was to examine bacterial killing and emergence of resistance with clinically 
relevant dosing regimens in the presence of various levels of renal function, fCmin/MIC ratios 
of ≥2 (i.e. %100 fT>2× MIC) for meropenem and ≥5 for piperacillin/tazobactam were observed 
to suppress bacterial regrowth. In the present study meropenem concentrations of 2 – 8× 
MIC (i.e. %100 fT>2-8× MIC) were required to suppress regrowth for most isolates at 24 and 48 
h, whereas for piperacillin/tazobactam concentrations of 4 - 16× MIC were required for all 
isolates at both time points. Thus the values obtained in the HFIM against a single isolate 
are within the concentration ranges observed in the present study which used a much larger 
number of P. aeruginosa and E. coli isolates (500-fold MIC range) and fixed concentrations 
of each antibiotic.  
With the exception of a few β-lactams such as cefepime and imipenem where there 
are consistent concerns regarding neurotoxicity [29, 30], β-lactams have a wide safety 
margin that can allow safe exposures to concentrations several multiples above the 
concentrations aimed for with standard dosing. The question thus remains, should we be 
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targeting concentrations of β-lactams several-fold above the MIC for more effective therapy, 
especially for the minimization of resistance? In theory concentrations above the mutant 
prevention concentration, which is considerably higher than the MIC, would be expected to 
suppress the emergence of resistant bacteria [31]. However, there have been concerns 
regarding the practicality of using this as a dosing target due to the risk of toxicity associated 
with the very high concentrations that may be required for pathogens such as P. aeruginosa, 
particularly in critically ill patients who are often infected by less susceptible isolates. Further 
pre-clinical studies would be needed before such high dose regimens could be trialled in 
patients.  
Although this study is indicative of the exposure-response relationships between the 
pathogens and study antibiotics, it has limitations as far as direct extrapolation to the clinical 
scenario is concerned. While most antibiotics are administered clinically for longer than the 
48 h period examined here, our results are likely to be indicative for the possible emergence 
of resistance with empiric therapy until the identity and susceptibilities of the causative 
pathogen are known (typically within 48 h). Importantly, the static nature of the experiments 
fails to simulate the dynamic concentrations of antibiotics in patients following intermittent 
dosing and thus future experiments in dynamic systems such as the HFIM are warranted. 
Additionally there is a lack of an immune system, in particular granulocytes, which play a 
central role in control of bacterial infections. Bacterial killing by granulocytes is a saturable 
process [32, 33] and, given antibiotics work in combination with the host immunity for 
eradicating the pathogen population after initial antibiotic kill, suppression of regrowth of 
resistant organisms may enable the immune system to also eradicate a resistant sub-
population. Drusano et al. [32] recently demonstrated for P. aeruginosa and Staphylococcus 
aureus that granulocytes can kill up to 50 cfu per gram of tissue per day and, consequently, 
if the antimicrobial treatment decreases the total population of the organism to ~102 – 103 
cfu, the immune system may be able to eradicate any residual population with minimal 
amplification of resistant mutants. Thus, achieving concentrations which prevent the rapid 
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regrowth that would otherwise occur may allow the immune system time to clear the 
infection. This observation suggests that prolonged treatment duration with exposures at, or 
close to, the MIC may be less important compared to higher exposures suppressing 
regrowth in the first few days of treatment; the latter may allow a shorter treatment duration 
to eradicate the pathogen. Indeed, other recent findings with β-lactams support treatment 
with a sufficiently effective high exposure for the shortest possible duration [28]. 
5. Conclusion 
This study has indicated that fixed concentrations of piperacillin/tazobactam and 
meropenem well above the MIC (i.e. 4× to 16× MIC for piperacillin/tazobactam and 2× to 64× 
MIC for meropenem) suppress regrowth of clinical isolates of P. aeruginosa and E. coli out 
to 48 h. Our findings suggest a potential benefit of targeting higher β-lactam concentrations 
beyond those required for maximum initial killing to suppress regrowth of resistant sub-
populations. Further preclinical investigations in dynamic in vitro models such as the hollow 
fibre infection model [34] to characterise the effect of changing antibiotic concentrations 
above the MIC on bacterial killing and emergence of resistance against a large number of 
isolates are urgently required. Such data is essential to support later clinical outcome studies 
that test the utility of novel dosing regimens and PK/PD targets especially as they relate to 
suppression of resistance. 
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Highlights 
 We identified strain-dependent concentrations required to suppress regrowth. 
 Concentrations suppressing regrowth were typically ≥8×MIC. 
 Regrowth with resistance occurred at lower concentrations despite initial killing. 
 A benefit of higher β-lactam concentrations is proposed. 
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